These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Chronic Migraine: A Real-World Retrospective Chart Review. Salim A; Hennessy E; Sonneborn C; Hogue O; Biswas S; Mays M; Suneja A; Ahmed Z; Mata IF CNS Drugs; 2024 Jun; 38(6):481-491. PubMed ID: 38583127 [TBL] [Abstract][Full Text] [Related]
25. Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study. Iannone LF; Burgalassi A; Vigani G; Tabasso G; De Cesaris F; Chiarugi A; Geppetti P Cephalalgia; 2023 Apr; 43(4):3331024231160519. PubMed ID: 36918752 [TBL] [Abstract][Full Text] [Related]
26. Erenumab in the treatment of migraine. Jain S; Yuan H; Spare N; Silberstein SD Pain Manag; 2018 Nov; 8(6):415-426. PubMed ID: 30235976 [TBL] [Abstract][Full Text] [Related]
28. Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study. Barbanti P; Aurilia C; Egeo G; Proietti S; D'Onofrio F; Torelli P; Aguggia M; Bertuzzo D; Finocchi C; Trimboli M; Cevoli S; Fiorentini G; Orlando B; Zucco M; Di Clemente L; Cetta I; Colombo B; di Poggio MLB; Favoni V; Grazzi L; Salerno A; Carnevale A; Robotti M; Frediani F; Altamura C; Filippi M; Vernieri F; Bonassi S; J Neurol; 2024 May; 271(5):2434-2443. PubMed ID: 38231271 [TBL] [Abstract][Full Text] [Related]
29. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Edvinsson L; Haanes KA; Warfvinge K; Krause DN Nat Rev Neurol; 2018 Jun; 14(6):338-350. PubMed ID: 29691490 [TBL] [Abstract][Full Text] [Related]
30. Therapeutic antibodies against CGRP or its receptor. Bigal ME; Walter S; Rapoport AM Br J Clin Pharmacol; 2015 Jun; 79(6):886-95. PubMed ID: 25614243 [TBL] [Abstract][Full Text] [Related]
31. Real-world experience with calcitonin gene-related peptide-targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centers. Shibata M; Fujita K; Hoshino E; Minami K; Koizumi K; Okada S; Sakai F BMC Neurol; 2024 Jan; 24(1):32. PubMed ID: 38238659 [TBL] [Abstract][Full Text] [Related]
32. Anti-calcitonin gene-related peptide monoclonal antibodies for neuropathic pain in patients with migraine headache. Kang SA; Govindarajan R Muscle Nerve; 2021 Apr; 63(4):563-567. PubMed ID: 33347632 [TBL] [Abstract][Full Text] [Related]
33. Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience. Raffaelli B; Fitzek M; Overeem LH; Storch E; Terhart M; Reuter U J Headache Pain; 2023 Feb; 24(1):16. PubMed ID: 36843007 [TBL] [Abstract][Full Text] [Related]
34. New drugs targeting calcitonin gene-related peptide for the management of migraines. Tana C; Cipollone F; Giamberardino MA; Martelletti P Expert Opin Emerg Drugs; 2023 Dec; 28(4):233-240. PubMed ID: 37996401 [TBL] [Abstract][Full Text] [Related]
35. Impact of multiple treatment cycles with anti-CGRP monoclonal antibodies on migraine course: focus on discontinuation periods. Insights from the multicenter, prospective, I-GRAINE study. Barbanti P; Aurilia C; Egeo G; Proietti S; Torelli P; d'Onofrio F; Carnevale A; Tavani S; Orlando B; Fiorentini G; Colombo B; Filippi M; Bonassi S; Cevoli S; J Neurol; 2024 May; 271(5):2605-2614. PubMed ID: 38342785 [TBL] [Abstract][Full Text] [Related]
36. CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention. Caronna E; Alpuente A; Torres-Ferrus M; Pozo-Rosich P Handb Clin Neurol; 2024; 199():107-124. PubMed ID: 38307640 [TBL] [Abstract][Full Text] [Related]
37. Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodies. Nsaka M; Scheffler A; Wurthmann S; Schenk H; Kleinschnitz C; Glas M; Holle D Brain Behav; 2022 Jul; 12(7):e2662. PubMed ID: 35687795 [TBL] [Abstract][Full Text] [Related]
38. Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway. Waliszewska-Prosół M; Martelletti P Dent Med Probl; 2024; 61(1):9-11. PubMed ID: 38284301 [TBL] [Abstract][Full Text] [Related]
39. Direct cost and healthcare resource utilization of patients with migraine before treatment initiation with calcitonin gene-related peptide monoclonal antibodies by the number of prior preventive migraine medication classes. Foster SA; Hoyt M; Ye W; Mason O; Ford JH Curr Med Res Opin; 2022 May; 38(5):653-660. PubMed ID: 34761723 [TBL] [Abstract][Full Text] [Related]
40. Switching OnabotulinumtoxinA to Monoclonal Anti-CGRP Antibodies in Drug-Resistant Chronic Migraine. Iannone LF; Fattori D; Marangoni M; Benemei S; Chiarugi A; Geppetti P; De Cesaris F CNS Drugs; 2023 Feb; 37(2):189-202. PubMed ID: 36656298 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]